JP2021513077A - 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー - Google Patents
認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー Download PDFInfo
- Publication number
- JP2021513077A JP2021513077A JP2020542645A JP2020542645A JP2021513077A JP 2021513077 A JP2021513077 A JP 2021513077A JP 2020542645 A JP2020542645 A JP 2020542645A JP 2020542645 A JP2020542645 A JP 2020542645A JP 2021513077 A JP2021513077 A JP 2021513077A
- Authority
- JP
- Japan
- Prior art keywords
- adm
- dementia
- antibody
- adrenomedullin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023174585A JP2024001208A (ja) | 2018-02-08 | 2023-10-06 | 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155682 | 2018-02-08 | ||
| EP18155682.0 | 2018-02-08 | ||
| PCT/EP2019/052982 WO2019154900A1 (en) | 2018-02-08 | 2019-02-07 | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174585A Division JP2024001208A (ja) | 2018-02-08 | 2023-10-06 | 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513077A true JP2021513077A (ja) | 2021-05-20 |
| JP2021513077A5 JP2021513077A5 (cg-RX-API-DMAC7.html) | 2022-08-04 |
Family
ID=61188647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542645A Pending JP2021513077A (ja) | 2018-02-08 | 2019-02-07 | 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー |
| JP2023174585A Pending JP2024001208A (ja) | 2018-02-08 | 2023-10-06 | 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174585A Pending JP2024001208A (ja) | 2018-02-08 | 2023-10-06 | 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210302440A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3749959A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021513077A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102717599B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN119770645A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019219071A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020014940A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3090736A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL276564A (cg-RX-API-DMAC7.html) |
| MX (1) | MX421834B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202006686SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019154900A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4110372A1 (en) * | 2020-02-26 | 2023-01-04 | PAM Theragnostics GmbH | Use of peptidylglycine alpha-amidating monooxygenase (pam) for therapeutic purpose |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| JP2023515981A (ja) | 2020-02-26 | 2023-04-17 | ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ペプチジルグリシンαアミド化モノオキシゲナーゼ(PAM)を決定する方法および診断目的でのその使用 |
| US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| EP4680966A1 (en) | 2023-03-17 | 2026-01-21 | PAM Theragnostics GmbH | Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose |
| WO2025133203A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Compounds and methods for a long-lasting pam |
| WO2025133225A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam) |
| WO2026099249A1 (en) | 2024-11-05 | 2026-05-15 | Pam Theragnostics Gmbh | Modified and unmodified peptidylglycine alpha-amidating monooxygenase (pam) for use in subjects having increased amyloid-beta and/or phospho-tau-protein load and/or neuroinflammation |
| WO2026099243A1 (en) | 2024-11-05 | 2026-05-15 | Pam Theragnostics Gmbh | Modified and unmodified peptidyl-glycine alpha-amidating monooxygenase (pam) for use in the treatment or prevention of cerebral hypoperfusion for the improvement of cerebral blood flow (cbf) |
| WO2026132535A1 (en) | 2024-12-20 | 2026-06-25 | B.R.A.H.M.S Gmbh | Pro-adrenomedullin and fragment(s) thereof for diagnosis and/or prognosis of a central nervous system inflammation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009503524A (ja) * | 2005-08-01 | 2009-01-29 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 神経変性疾患の診断のためのinvitro方法 |
| JP2009540309A (ja) * | 2006-06-16 | 2009-11-19 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 神経変性障害の診断および早期診断のためのinvitroマルチパラメータ測定法 |
| JP2011511282A (ja) * | 2008-02-01 | 2011-04-07 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療の必要な軽度認知障害患者の特定方法とかかる患者の治療 |
| US20130315912A1 (en) * | 2010-08-30 | 2013-11-28 | Centre National De La Recherche Scientifique | Antibodies that Bind to Adrenomedullin and to Adrenomedullin Receptors and the Uses Thereof as Drugs |
| JP2014533827A (ja) * | 2011-11-16 | 2014-12-15 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法 |
| JP2014533671A (ja) * | 2011-11-16 | 2014-12-15 | アドレノメト アクチェンゲゼルシャフト | 治療法における使用のための抗アドレノメデュリン(ADM)抗体、抗ADM抗体フラグメント又は抗ADM非Ig足場 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CN1628126A (zh) | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| US20090306227A1 (en) | 2005-08-31 | 2009-12-10 | Toshiyuki Ioka | Tablet for removing tongue coating |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| BR112012014417B1 (pt) | 2009-12-14 | 2021-11-09 | Scil Proteins Gmbh | Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| US20160230227A1 (en) * | 2012-12-21 | 2016-08-11 | The New York Stem Cell Foundation | Methods of treating alzheimer's disease |
| CN109716136B (zh) * | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
-
2019
- 2019-02-07 KR KR1020207025729A patent/KR102717599B1/ko active Active
- 2019-02-07 AU AU2019219071A patent/AU2019219071A1/en not_active Abandoned
- 2019-02-07 JP JP2020542645A patent/JP2021513077A/ja active Pending
- 2019-02-07 US US16/968,483 patent/US20210302440A1/en active Pending
- 2019-02-07 CA CA3090736A patent/CA3090736A1/en active Pending
- 2019-02-07 BR BR112020014940-3A patent/BR112020014940A2/pt not_active IP Right Cessation
- 2019-02-07 CN CN202411684173.XA patent/CN119770645A/zh active Pending
- 2019-02-07 EP EP19702467.2A patent/EP3749959A1/en active Pending
- 2019-02-07 CN CN201980012542.1A patent/CN111902721B/zh active Active
- 2019-02-07 MX MX2020008345A patent/MX421834B/es unknown
- 2019-02-07 SG SG11202006686SA patent/SG11202006686SA/en unknown
- 2019-02-07 WO PCT/EP2019/052982 patent/WO2019154900A1/en not_active Ceased
-
2020
- 2020-08-06 IL IL276564A patent/IL276564A/en unknown
-
2022
- 2022-12-30 US US18/148,633 patent/US20230221339A1/en active Pending
-
2023
- 2023-10-06 JP JP2023174585A patent/JP2024001208A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009503524A (ja) * | 2005-08-01 | 2009-01-29 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 神経変性疾患の診断のためのinvitro方法 |
| JP2009540309A (ja) * | 2006-06-16 | 2009-11-19 | ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト | 神経変性障害の診断および早期診断のためのinvitroマルチパラメータ測定法 |
| JP2011511282A (ja) * | 2008-02-01 | 2011-04-07 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療の必要な軽度認知障害患者の特定方法とかかる患者の治療 |
| US20130315912A1 (en) * | 2010-08-30 | 2013-11-28 | Centre National De La Recherche Scientifique | Antibodies that Bind to Adrenomedullin and to Adrenomedullin Receptors and the Uses Thereof as Drugs |
| JP2014533827A (ja) * | 2011-11-16 | 2014-12-15 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法 |
| JP2014533671A (ja) * | 2011-11-16 | 2014-12-15 | アドレノメト アクチェンゲゼルシャフト | 治療法における使用のための抗アドレノメデュリン(ADM)抗体、抗ADM抗体フラグメント又は抗ADM非Ig足場 |
Non-Patent Citations (2)
| Title |
|---|
| HOLM, H. ET AL.: "Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based pr", JOURNAL OF INTERNATIONAL MEDICINE, vol. 282, JPN6022054590, 2017, pages 94 - 101, ISSN: 0004959634 * |
| ICHIKI, Y. ET AL.: "Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma", FEBS LETTERS, vol. 338, JPN6022054591, 1994, pages 6 - 10, ISSN: 0004959633 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102717599B1 (ko) | 2024-10-14 |
| CN111902721B (zh) | 2024-12-13 |
| MX421834B (es) | 2025-03-14 |
| IL276564A (en) | 2020-09-30 |
| CN119770645A (zh) | 2025-04-08 |
| CA3090736A1 (en) | 2019-08-15 |
| KR20200135947A (ko) | 2020-12-04 |
| RU2020129154A (ru) | 2022-03-10 |
| CN111902721A (zh) | 2020-11-06 |
| MX2020008345A (es) | 2020-09-25 |
| JP2024001208A (ja) | 2024-01-09 |
| WO2019154900A1 (en) | 2019-08-15 |
| US20210302440A1 (en) | 2021-09-30 |
| BR112020014940A2 (pt) | 2020-12-08 |
| EP3749959A1 (en) | 2020-12-16 |
| RU2020129154A3 (cg-RX-API-DMAC7.html) | 2022-03-10 |
| US20230221339A1 (en) | 2023-07-13 |
| AU2019219071A1 (en) | 2020-07-30 |
| SG11202006686SA (en) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230221339A1 (en) | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-andrenomedullin binder for use in therapy or prevention of dementia | |
| JP7654597B2 (ja) | 急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン | |
| JP6336911B2 (ja) | アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法 | |
| KR20200130354A (ko) | 신경퇴행을 검출하기 위한 분석 | |
| JP2025530718A (ja) | 抗タウmtbr抗体、ならびにタウの切断された断片の検出方法およびその用途 | |
| CN116348769A (zh) | 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定 | |
| US20220268761A1 (en) | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder | |
| JPWO2011045945A1 (ja) | アミロイドβのターン構造を認識する抗体 | |
| JP2026035582A (ja) | ショックを患っている患者におけるnt-adm抗体治療法ガイダンス、モニタリング、及び層別化のためのdpp3 | |
| US20230357383A1 (en) | Anti-ADM-antibodies binding to the free N-terminus for accelerated transition of ADM-Gly to bio-ADM in patients with ADM-Gly/ bio-ADM ratio above a threshold and combination with vitamin C | |
| US20220260593A1 (en) | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia | |
| RU2811309C2 (ru) | Адреномедуллин (adm) для диагностики и/или прогнозирования деменции и антиадреномедуллин-связующий агент для применения в терапии или профилактике деменции | |
| HK40121614A (en) | Adrenomedullin for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia | |
| HK40034157A (en) | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia | |
| RU2835424C2 (ru) | Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью | |
| RU2776811C2 (ru) | Мониторинг терапии при лечении связывающим веществом против адреномедуллина (adm) | |
| EA049359B1 (ru) | Анализ проб, полученных из крови, для обнаружения таупатии или амилоидогенного заболевания | |
| HK40096066A (en) | Blood-based assay for detecting tauopathy or amyloidogenic disease | |
| CN119604526A (zh) | 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 | |
| HK40031761A (en) | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder | |
| HK40005377B (en) | Adrenomedullin for assessing congestion in a subject with acute heart failure | |
| HK1202624B (en) | Adrenomedullin assays and methods for determining mature adrenomedullin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220727 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230428 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231013 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231031 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20231201 |